2023
Hepatic Hypertrophy in Normal and Cirrhotic Livers Following Portal Vein Embolization: Comparative Assessment of 2 Different Embolic Regimens in a Large Animal Model
Kuhn T, Kahl V, Wang Y, Berz A, Shewarega A, Santana J, Antoch G, Chapiro J, Schlachter T, Madoff D. Hepatic Hypertrophy in Normal and Cirrhotic Livers Following Portal Vein Embolization: Comparative Assessment of 2 Different Embolic Regimens in a Large Animal Model. Journal Of Vascular And Interventional Radiology 2023, 34: 2162-2172.e2. PMID: 37634850, DOI: 10.1016/j.jvir.2023.08.024.Peer-Reviewed Original ResearchConceptsPortal vein embolizationFuture liver remnantVein embolizationLiver remnantCirrhotic liverStandardized future liver remnantNon-cirrhotic groupImmune cell infiltrationNon-cirrhotic liverN-butyl cyanoacrylateT-testFemale Yorkshire pigsLarge animal modelLarge animal studiesStudent's t-testCirrhotic groupEmbolized lobeBaseline percentageHepatic hypertrophyCell infiltrationBaseline CTKi-67Preclinical studiesInstitutional Animal CareFLR increase
2022
Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy
Korenblik R, Olij B, Aldrighetti LA, Hilal MA, Ahle M, Arslan B, van Baardewijk LJ, Baclija I, Bent C, Bertrand CL, Björnsson B, de Boer MT, de Boer SW, Bokkers RPH, Rinkes IHMB, Breitenstein S, Bruijnen RCG, Bruners P, Büchler MW, Camacho JC, Cappelli A, Carling U, Chan BKY, Chang DH, choi J, Font JC, Crawford M, Croagh D, Cugat E, Davis R, De Boo DW, De Cobelli F, De Wispelaere JF, van Delden OM, Delle M, Detry O, Díaz-Nieto R, Dili A, Erdmann JI, Fisher O, Fondevila C, Fretland Å, Borobia FG, Gelabert A, Gérard L, Giuliante F, Gobardhan PD, Gómez F, Grünberger T, Grünhagen DJ, Guitart J, Hagendoorn J, Heil J, Heise D, Herrero E, Hess GF, Hoffmann MH, Iezzi R, Imani F, Nguyen J, Jovine E, Kalff JC, Kazemier G, Kingham TP, Kleeff J, Kollmar O, Leclercq WKG, Ben SL, Lucidi V, MacDonald A, Madoff DC, Manekeller S, Martel G, Mehrabi A, Mehrzad H, Meijerink MR, Menon K, Metrakos P, Meyer C, Moelker A, Modi S, Montanari N, Navines J, Neumann UP, Peddu P, Primrose JN, Qu X, Raptis D, Ratti F, Ridouani F, Rogan C, Ronellenfitsch U, Ryan S, Sallemi C, Moragues JS, Sandström P, Sarriá L, Schnitzbauer A, Serenari M, Serrablo A, Smits MLJ, Sparrelid E, Spüntrup E, Stavrou GA, Sutcliffe RP, Tancredi I, Tasse JC, Udupa V, Valenti D, Fundora Y, Vogl TJ, Wang X, White SA, Wohlgemuth WA, Yu D, Zijlstra IAJ, Binkert CA, Bemelmans MHA, van der Leij C, Schadde E, van Dam RM. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy. CardioVascular And Interventional Radiology 2022, 45: 1391-1398. PMID: 35790566, PMCID: PMC9458562, DOI: 10.1007/s00270-022-03176-1.Peer-Reviewed Original ResearchConceptsFuture liver remnant hypertrophyHepatic vein embolizationMulticenter prospective single-arm trialResectable colorectal cancer liver metastasesColorectal cancer liver metastasesProspective single-arm trialFeasibility of resectionCancer liver metastasesDisease-free survivalSingle-arm trialSmall FLRPrimary endpointSecondary endpointsFLR hypertrophyLiver metastasesOverall survivalProspective trialVein embolizationLiver functionSafety profileArm trialLiver volumeWeek 1Week 3Study centers
2021
Systematic Reviews and Meta-Analyses of Portal Vein Embolization, Associated Liver Partition and Portal Vein Ligation, and Radiation Lobectomy Outcomes in Hepatocellular Carcinoma Patients
Charalel RA, Sung J, Askin G, Jo J, Mitry M, Chung C, Tmanova L, Madoff DC. Systematic Reviews and Meta-Analyses of Portal Vein Embolization, Associated Liver Partition and Portal Vein Ligation, and Radiation Lobectomy Outcomes in Hepatocellular Carcinoma Patients. Current Oncology Reports 2021, 23: 135. PMID: 34716800, DOI: 10.1007/s11912-021-01075-1.Peer-Reviewed Original ResearchConceptsPortal vein embolizationAssociated liver partitionPortal vein ligationHepatocellular carcinoma patientsSystematic reviewVein embolizationCarcinoma patientsMajor complicationsPooled proportionVein ligationLiver partitionLow major complication rateMajor complication ratePurpose of ReviewToRandom-effects modelWeb of ScienceEffective hypertrophyFLR hypertrophyComplication rateOvid EmbaseCochrane LibraryHCC patientsLiver hypertrophyOvid MEDLINEInclusion criteria
2005
Transhepatic Ipsilateral Right Portal Vein Embolization Extended to Segment IV: Improving Hypertrophy and Resection Outcomes with Spherical Particles and Coils
Madoff DC, Abdalla EK, Gupta S, Wu TT, Morris JS, Denys A, Wallace MJ, Morello FA, Ahrar K, Murthy R, Lunagomez S, Hicks ME, Vauthey JN. Transhepatic Ipsilateral Right Portal Vein Embolization Extended to Segment IV: Improving Hypertrophy and Resection Outcomes with Spherical Particles and Coils. Journal Of Vascular And Interventional Radiology 2005, 16: 215-225. PMID: 15713922, DOI: 10.1097/01.rvi.0000147067.79223.85.Peer-Reviewed Original ResearchMeSH KeywordsAcrylic ResinsAdultAgedBile Duct NeoplasmsCarcinoma, HepatocellularCause of DeathEmbolization, TherapeuticFemaleFollow-Up StudiesGelatinHepatectomyHumansHypertrophyLength of StayLiverLiver NeoplasmsMaleMicrospheresMiddle AgedPolyvinyl AlcoholPortal VeinRetrospective StudiesSafetyTomography, Spiral ComputedTreatment OutcomeConceptsTotal estimated liver volumeRight portal vein embolizationTris-acryl microspheresRight PVEPortal vein embolizationRight hepatectomyFLR volumeResection rateVein embolizationLiver volumeEstimated liver volumeMalignant hepatobiliary diseaseProgressive liver insufficiencyMedian hospital stayPercent of patientsExtended right hepatectomyResult of sepsisFuture liver remnantPostembolization syndromeTomographic volumetryHospital stayFLR hypertrophyPostoperative outcomesResection outcomesBiliary cancer